• Molecular NameFloxuridine
  • Synonym5 Fluorodeoxyuridine; 5FDU; Deoxyfluorouridine; FDUR; FDURD; Floxiridina [INN-Spanish]; Floxuridin; Floxuridinum [INN-Latin]; Fluorodeoxyuridine; Fluoruridine Deoxyribose
  • Weight246.194
  • Drugbank_IDDB00322
  • ACS_NO50-91-9
  • Show 2D model
  • LogP (experiment)-1.249
  • LogP (predicted, AB/LogP v2.0)-1.17
  • pka7.44
  • LogD (pH=7, predicted)-1.25
  • Solubility (experiment)11.9 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-0.25
  • LogSw (predicted, AB/LogsW2.0)83.01
  • Sw (mg/ml) (predicted, ACD/Labs)109.65
  • No.of HBond Donors3
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds2
  • TPSA99.1
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn oncology drug that belongs to the class known as antimetabolites. The drug is most often used in the treatment of colorectal cancer.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability90.0
  • Protein binding11.5
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic
  • Half life30 h
  • ExcretionRenal 61–88%
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySigns of overdose include nausea, vomiting, diarrhea, gastrointestinal ulceration and bleeding, and bone marrow depression (including thrombocytopenia, leukopenia and agranulocytosis).
  • LD50 (rat)215 mg/kg
  • LD50 (mouse)N/A